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Protective CD8þ T-cell immunity to human
malaria induced by chimpanzee adenovirus-MVA
immunisation
Katie J. Ewer1,*, Geraldine A. O’Hara2,*, Christopher J.A. Duncan2,*, Katharine A. Collins1, Susanne H. Sheehy2,
Arturo Reyes-Sandoval1, Anna L. Goodman1,2, Nick J. Edwards1, Sean C. Elias1, Fenella D. Halstead1,
Rhea J. Longley1, Rosalind Rowland2, Ian D. Poulton2, Simon J. Draper1, Andrew M. Blagborough3, Eleanor Berrie4,
Sarah Moyle4, Nicola Williams5, Loredana Siani6, Antonella Folgori6, Stefano Colloca6, Robert E. Sinden1,3,
Alison M. Lawrie2, Riccardo Cortese6, Sarah C. Gilbert1, Alfredo Nicosia6,7,8 & Adrian V.S. Hill1,2
Induction of antigen-speciﬁc CD8þ Tcells offers the prospect of immunization against many
infectious diseases, but no subunit vaccine has induced CD8þ T cells that correlate with
efﬁcacy in humans. Here we demonstrate that a replication-deﬁcient chimpanzee adenovirus
vector followed by a modiﬁed vaccinia virus Ankara booster induces exceptionally high fre-
quency T-cell responses (median 42400 SFC/106 peripheral blood mononuclear cells) to
the liver-stage Plasmodium falciparum malaria antigen ME-TRAP. It induces sterile protective
efﬁcacy against heterologous strain sporozoites in three vaccinees (3/14, 21%), and delays
time to patency through substantial reduction of liver-stage parasite burden in ﬁve more
(5/14, 36%), P¼0.008 compared with controls. The frequency of monofunctional inter-
feron-g-producing CD8þ T cells, but not antibodies, correlates with sterile protection
and delay in time to patency (Pcorrected¼0.005). Vaccine-induced CD8þ T cells provide
protection against human malaria, suggesting that a major limitation of previous vaccination
approaches has been the insufﬁcient magnitude of induced T cells.
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A
major goal of modern vaccinology is to extend the
capacity of current vaccines to include provision of
protective immunity mediated by CD8þ T cells1. CD8þ
T cells provide protective immunity against a wide range of
infectious pathogens such as HIV, inﬂuenza virus and CMV and
some tumours, in many animal species and humans, suggesting
that induction of CD8þ T cells by immunization could provide
prophylactic or even therapeutic efﬁcacy against a wide range of
pathogens, particularly those that survive inside cells2–6. The
broader range of expression of HLA class I molecules, on almost
all nucleated cells, makes CD8þ T cells more desirable effectors
than CD4þ T cells, which can target only HLA class II-positive
cells, and CD8þ T cell memory is generally very durable7.
However, despite substantial efforts to harness cellular immunity
as an effector mechanism for a new generation of T–cell-based
vaccines, almost all licensed vaccines provide protection that
appears to be primarily mediated by antibodies. The sole
exception, the BCG vaccine against tuberculosis, appears to
protect primarily by induction of CD4þ rather than CD8þ
T cells8.
A wide variety of vaccine technologies have been found to
provide CD8þ T-cell-dependent protection in small animal
models of infection and cancer but translating this to humans has
been problematic. It remains unclear whether the main problem
is induction of a CD8þ T cell response of the wrong quality9 or
insufﬁcient magnitude10. Interestingly, the levels of CD8þ T cell
responses inducible in mice are typically at least an order of
magnitude greater than those in humans11, and rare examples of
T-cell-mediated efﬁcacy in non-human primates12 have induced
levels of CD8þ T-cell response higher than those reported in
almost all clinical trials.
CD8þ T cells targeting the liver stage of malaria infection are
protective in animal models and can be induced by both
irradiated sporozoites and several subunit vaccines13. Several
antigens including thrombospondin-related adhesion protein
(TRAP)14 are protective. A particularly effective means of
inducing CD8þ T cells was discovered in murine malaria
models whereby two replicating15 or non-replicating11,14,16 viral
vectors were found to induce CD8þ T-cell mediated immunity
provided that a poxvirus vector was used as the boosting agent.
In human clinical trials we have found that such prime-boost
approaches using either plasmid DNA or a fowlpox vector to
prime immune responses and the replication-deﬁcient modiﬁed
virus Ankara (MVA) strain of vaccinia as a boosting vector could
induce modest protective efﬁcacy, manifested mainly as delay in
time to patency, against controlled human malaria infection
(CHMI) with a well-deﬁned ﬁve-bite sporozoite challenge
protocol17,18. However, this efﬁcacy was associated with CD4þ
T-cell responses while induction of CD8þ T cells was very weak.
More effective priming agents for induction of CD8þ T cells in
pre-clinical studies are human16 or, more recently identiﬁed,
chimpanzee-derived11,19 adenoviruses.
The induction of higher-level protective efﬁcacy with vectors is
a priority for malaria vaccine development as only one malaria
vaccine has induced repeatable efﬁcacy in ﬁeld trials20,21; this
protective efﬁcacy is associated with high titres of antibodies
against sporozoites but no CD8þ T cell induction. Addition of a
partially effective liver-stage component to this anti-sporozoite
vaccine might provide substantially higher efﬁcacy22.
We assess here the efﬁcacy of chimpanzee-derived simian
adenovirus 63 (ChAd63, previously denoted AdCh63) expressing
the ME-TRAP insert17,18,23 with MVA expressing the same insert
(MVA ME-TRAP) in a heterologous prime-boost regimen. This
open label phase IIa sporozoite (CHMI) study followed successful
pre-clinical studies in mice11 and rhesus macaques24 and a phase
I dose escalation study23 that showed adequate safety and
exceptional T-cell immunogenicity. We demonstrate that using
this approach, protective efﬁcacy against heterologous strain
sporozoite CHMI is observed in more than half of the prime-
boost vaccinees (n¼ 14, P¼ 0.008, log-rank Mantel Cox test),
and protection correlates with antigen-speciﬁc interferon gamma
(IFNg)-producing CD8þ T cells (Po0.001, two-tailed
Spearman’s correlation), but not with antibodies.
Results
Study design and vaccine safety. We conducted the efﬁcacy
study in two parts (challenges A and B) (Supplementary Fig. S1a).
We ﬁrst compared this adenovirus prime-MVA boost regimen,
using one dose of each vaccine 8 weeks apart (n¼ 8), with a single
dose of the adenovirus vector used alone (n¼ 10) with unvacci-
nated controls (n¼ 6) in challenge A, and then repeated the
comparison between the prime-boost regimen (n¼ 6) and con-
trols in challenge B to conﬁrm our ﬁndings. We challenged
prime-boost vaccinees 2–3 weeks (range 14–21 days) following
MVA vaccination (day 70–77 post-ChAd63), as before17,18, and
adenovirus-alone volunteers 28 days (range 21–28) following
priming vaccination for optimal comparability, as this
encompassed the period of peak immunogenicity identiﬁed in a
phase I study23. Both vaccines were well tolerated (Supplementary
Fig. S1b,c).
Cellular and humoral immunity induced by vaccination.
Immune responses to ME-TRAP in the prime-boost vaccinated
group (ChAd63-MVA) peaked 1 week after boosting at a median
of 2,436 (inter-quartile range (IQR): 1,064–3,862) spot-forming
cells (SFC) per million peripheral blood mononuclear cells
(PBMC) in an ex vivo IFNg enzyme-linked immunospot (ELI-
SPOT) assay, compared with a median of 864 SFC/106 PBMC
(IQR: 710–1,910) in the prime-only group (ChAd63) (P¼ 0.04,
two-tailed Mann–Whitney; Fig. 1a). Follow-up of all vaccinees to
day 150 post challenge showed good maintenance of effector
T-cell frequencies with responses in the prime-boost group of 712
SFC/106 PBMC (IQR: 310–1,412) representing 50% of the
response at the time of challenge. This level of immunogenicity is
considerably higher than that found with previous prime-boost
regimes with the same antigenic insert17,18, and also appears to be
higher than in all reported studies of vectored vaccines for HIV25
and malignant diseases26. We observed ELISPOT responses to
TRAP in 100% of vaccinated volunteers and multiple peptide
pools (43/6) were recognized in every case, both at the peak of
the response and the time of CHMI. Epitope mapping with
individual 20mer peptides identiﬁed at least 16 different potential
determinants. At time of challenge in part B, mapping with
individual 20mer peptides showed an average of 7.5 peptides
recognized per volunteer (range 3–18), although the use of
overlapping peptides means that the number of actual epitopes
may be as much as 33% lower if an epitope was represented in
two adjacent pools. Boosting with MVA signiﬁcantly increased
the breadth of the response in the prime-boost group as measured
by an increase in the number of peptide pools recognized before
and after MVA (P¼ 0.012; two-tailed Mann–Whitney test;
Fig. 1b), and the magnitude of the ELISPOT response to TRAP
after adenovirus priming was strongly associated with the
subsequent response to MVA (rs¼ 0.70, P¼ 0.005 (two-tailed
Spearman’s correlation); Fig. 1c). T-cell responses targeted
predominantly the TRAP antigen rather than the ME string
(Fig. 1d). Responses to the heterologous 3D7 challenge strain
antigen were on average 73% of the response to the vaccine
strain antigen, T9/96 (Fig. 1e). Vaccination with ChAd63
ME-TRAP also induced modest detectable IgG antibody
responses to TRAP in 16/18 volunteers, and these levels were
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boosted twofold (17/18 responders) after MVA ME-TRAP
(measured in challenge A only; Fig. 1f) to a geometric
mean endpoint titre of 250. Neutralizing antibody (nAb) titres
to the adenovirus vector measured pre-vaccination in challenge
A were generally low as expected for a simian adenovirus
(median titre 74, IQR: 0–168) and these antibody levels did
not correlate negatively with the magnitude of vaccine-induced
T cell or antibody responses to TRAP, but a trend (rs¼ 0.79
P¼ 0.057, two-tailed Spearman’s correlation) towards higher
induced peak T cell responses to the insert was noted in those
with antibodies to the vector (Fig. 1g). In view of this lack of
impact of nAb titre on immunogenicity, we removed the
exclusion criterion of nAb titre 4200 for vaccinated volunteers
in challenge B and observed no attenuation of immunogenicity,
nor was there any relationship between nAb titre and time to
patency by blood ﬁlm.
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Figure 1 | Immunogenicity of prime-boost vaccination with ChAd63-MVA ME-TRAP. (a) Median ME-TRAP IFNg ex vivo ELISPOTresponses to the T9/96
strain for each group, P¼0.04 for peak immunogenicity (D28 for A (n¼ 10) and D63 for AM (n¼ 14)), *P¼0.012 for difference in immunogenicity
at D166, both two-tailed Mann–Whitney. (b) Breadth of TRAP-speciﬁc ELISPOT responses before (D14, D56) and after boosting (D63) with MVA
ME-TRAP, using T9/96 strain peptides, showing mean (±s.e.m.) number of pools recognized. (c) Correlation of peak ELISPOT responses to T9/96 TRAP
post-prime and at time of sporozoite challenge. (d) Individual responses to TRAP and ME at time of sporozoite challenge (data points in red
represent sterilely protected volunteers). (e) Median with IQR IFNg ELISPOT responses to TRAP peptides from the heterologous vaccine and challenge
strains of P. falciparum. (f) IgG antibodies to TRAP boosted by MVA compared with ChAd63 alone (medians); differences not statistically signiﬁcant.
(g) Spearman’s correlation of pre-existing antibodies to ChAd63 with peak vaccine-induced ELISPOT responses to TRAP (T9/96 strain).
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Protective efﬁcacy of ChAd63-MVA ME-TRAP against CHMI.
Overall, we exposed 24 vaccinees and 12 unvaccinated control
volunteers (6 in each challenge) to ﬁve infectious A. stephensi
mosquito bites in a standard procedure used in over 1,300 vaccine
trial subjects worldwide including 4300 at this centre
(Supplementary Fig. S1a). The TRAP antigen in the infecting
strain (3D7) differs by 37 amino acids (B6.5%) from the vaccine
strain (T9/96), thereby constituting a heterologous strain chal-
lenge17. As expected, all 12 non-immunized controls developed
malaria, as did all 10 vaccinees who received only a single
adenovirus immunization. Of the 14 prime-boost vaccinees, 3
(21.4%, 95% CI: 46.0–3.2%) were sterilely protected, 2/8 in
challenge A and 1/6 in challenge B, a statistically signiﬁcant
protection rate, which is higher than in all previous trials with
other vectored vaccine regimes (0–12.5%)17,18,27,28.
In addition ﬁve prime-boost vaccinees (36%, 95% CI: 64.4,
7.0%) developed malaria at day 14 or later, 42 days later than
unvaccinated control volunteers (2/8 challenge A, 3/6 challenge
B), a signiﬁcant delay to patent parasitaemia indicating a strong
vaccine-related biological impact on liver-stage parasites compar-
ing the ﬁve delayed vaccinees (14.6 days) to the control group
(11.8 days). Based on the 2.8 day difference in mean time to
parasitaemia, at a 12-fold parasite growth rate per 48 h29, there is
a 27-fold reduction in parasite density emerging from the liver
corresponding to a 96% reduction in liver parasite burden.
Kaplan–Meier survival analysis of time to parasitaemia, the
primary efﬁcacy endpoint of the trial, demonstrated signiﬁcant
delay in time to patent parasitaemia in the prime-boost group
compared with the unvaccinated control group as measured by
blood ﬁlm microscopy (P¼ 0.008, log-rank test, Fig. 2a). There
were no signiﬁcant differences in time to patency between the two
challenges for either prime-boost (P¼ 0.61) or control volunteers
(P¼ 0.14, both log-rank test).
This delay to patent parasitaemia among prime-boost vacci-
nees was also evident using a sensitive real-time quantitative PCR
assay of blood parasite densities30 to measure time to 420
parasites per ml as an endpoint (P¼ 0.016, log-rank test, Fig. 2b,
raw data shown in Supplementary Table S1). The clinical
impact of prime-boost was also reﬂected by group parasite
growth dynamics, with a signiﬁcant reduction in mean
parasite density measured by PCR over the second and third
parasite replication cycles in Ad-M recipients compared with
controls (P¼ 0.014 and 0.0003 two-tailed Mann–Whitney or
t-test for area under curve; Fig. 2c,d). This vaccine-induced
effect remained when sterilely protected vaccinees were removed
from the analysis (P¼ 0.03 and 0.01 two-tailed t-test for area
under curve during second and third replication cycles,
respectively; Fig. 2c,e). The area under the curve of parasite
density over the ﬁrst three replication cycles in infected
volunteers was signiﬁcantly negatively correlated with time to
blood-ﬁlm diagnosis (rs¼  0.63, Po0.002, two-tailed
Spearman’s correlation). Therefore, this substantial difference in
parasite densities between infected vaccinees and controls
at days 8–12 post challenge, shortly after parasites enter the
blood from the liver, provides further evidence of a signiﬁcant
vaccine effect.
We re-challenged both sterilely protected vaccinees from
challenge A 8 months after the ﬁrst sporozoite exposure: one
volunteer was sterilely protected again, and one delayed by 48 h
when compared with the controls (P¼ 0.034, log-rank test); the
sterilely protected vaccinee from challenge B also showed a
signiﬁcant delay to patency on re-challenge (day 14.0 compared
with a mean of 10.2 days for the controls in that challenge)
after an 8-month interval, indicating some maintenance of
protective immunity (overall P¼ 0.0047, log-rank test, for the
3 re-challengees compared with 12 controls).
Assessment of vaccine-induced correlates of protection. Ana-
lysis of immune responses by ﬂow cytometry showed that vac-
cination induced high frequencies of TRAP-speciﬁc CD4þ and
CD8þ T cells (Fig. 3a,b), containing IFNg, interleukin-2 (IL-2),
tumour necrosis factor-alpha (TNFa) or displaying CD107a, a
marker of the capacity of T cells for cytotoxic degranulation. A
sample gating strategy is shown in Supplementary Fig. S2. T cells
induced by the prime-boost regimen were more polyfunctional
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Figure 2 | Vaccine efﬁcacy assessments by time to microscopic patency
and PCR measures. Kaplan–Meier log-rank comparison of days to positive
blood ﬁlm (a) and 420 parasites per ml by PCR (b) between adenovirus-
MVA prime-boost (Ad-M) group (n¼ 14), adenovirus-only (Ad) group
(n¼ 10) and controls (n¼ 12). Mean days to positivity by blood ﬁlm: Ad-M
14.6 days (95% CI: 12.3–16.8), adenovirus-alone group (Ad) 11.3 days (95%
CI: 10.2–12.5), control group 11.8 days (95% CI: 10.8–12.7); and to 20
parasites per ml by PCR: Ad-M 11.6 days (95% CI: 8.5–14.7), Ad 7.8 days
(95% CI: 7.0–8.6), control group 8.1 days (95% CI: 4–8.8). (c) Group mean
log-transformed PCR data (error bars represent s.e.m.). Area under curve
analysis of parasite densities comparing controls to vaccinees (either
including (d) or excluding (e) volunteers that were sterilely protected) at
days 6.5–8 (ﬁrst cycle post hepatocyte release), days 8.5–10 (second cycle)
and 10.5–12 (third cycle) post challenge. Over the second and third cycles,
there is a signiﬁcant reduction in vaccinees’ parasite densities compared
with controls; the lack of signiﬁcance at cycle one probably reﬂects low
power due to very low parasite densities. Comparison of areas under curves
for all three cycles combined also shows a signiﬁcant reduction in parasite
densities between vaccinees and controls (P¼0.003 when including
sterilely protected vaccinees, P¼0.01 when excluding sterilely protected
vaccinees, (two-tailed t-test).
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than those induced by vaccination with ChAd63 alone (Fig. 3c,d).
The median frequency of polyfunctional CD4þ T cells contain-
ing IFNg, IL-2 or TNFa simultaneously at the time of challenge in
the prime-boost group was 0.1% of antigen-speciﬁc CD4þ T cells
(IQR: 0.02–0.24) compared with 0.04% (IQR: 0.02–0.25) for the
adenovirus-only group. Frequencies of polyfunctional CD8þ
T cells were also higher in the prime-boost group (median 0.03%,
IQR: 0–0.24) compared with 0.01% (IQR: 0–0.03) in the adeno-
virus-alone group. However, the total percentage of CD8þ T cells
containing IFNg in the prime-boost group was much higher
(median: 0.12% (IQR 0.05–0.7); mean: 0.36% (s.e.m. 0.12)),
representing exceptionally strong immunogenicity.
Both cellular and antibody responses at the time of challenge
were studied for their association with time to patent para-
sitaemia. Ex vivo and cultured IFNg ELISPOT responses to TRAP
(summed across the pools of peptides representing the T9/96
strain antigen) showed no statistically signiﬁcant association with
time to patency (Fig. 4a and Table 1). Antibodies to TRAP were
measured by ELISA in part A of the trial and did not correlate
with vaccine performance, so we focused on cellular immune
correlates in part B.
Further analysis of immune correlates of vaccine performance
included measures of polyfunctional as well as monofunctional
CD4þ and CD8þ T cells and mean ﬂuorescence intensity
(geometric and integrated). In part A, we analysed combined data
from all vaccinees and identiﬁed the frequency of CD8þ T cells
secreting IFNg, but not IL-2 or TNFa, as the strongest correlate
of time to patency (rs¼ 0.63, P¼ 0.005, two-tailed Spearman’s
correlation; Fig. 4b and Table 1). In the prime-boost group alone,
the association was also evident despite smaller numbers
(rs¼ 0.84, P¼ 0.011, two-tailed Spearman’s correlation). How-
ever, cytokine production on a per-cell basis was not associated
(Table 1), suggesting that the quantity of cytokine secreted alone
was not a key protective factor. This observation contrasts with
ﬁndings in murine leishmaniasis where polyfunctional CD4þ
T cells and quantity of cytokine secreted per cell were predictive
of protective vaccine efﬁcacy9, but is consistent with our recent
data in a murine malaria model11. Analysis of CD107aþ
expression at a later time point (150 days after challenge A)
showed that the frequency of these lytic CD8þ T cells also
correlated with efﬁcacy (rs¼ 0.61, P¼ 0.02, two-tailed
Spearman’s correlation; Fig. 4c). We then reassessed and
conﬁrmed the association between time to patency and CD8þ
T cells secreting IFNg alone in prime-boost vaccinees in challenge
B (rs¼ 0.64, P¼ 0.018, two-tailed Spearman’s correlation).
Analysis of the combined data from challenges A and B
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Figure 3 | Functionality of TRAP-speciﬁc CD4þ and CD8þ T cells. (a) Peak immunogenicity (day 63¼ 7 days after boosting) and (b) time of
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showed a very clear correlation both with time to patency
(rs¼ 0.81, P¼ 0.0005; Table 1) and PCR-quantiﬁed early blood
parasite density (rs¼  0.56, Po0.04, two-tailed Spearman’s
correlation, Fig. 4d). A secondary analysis of subgroups showed
that IFNg-secreting CD8þ T cells were also signiﬁcantly higher
both in vaccinees showing sterile (Po0.01) protection and also in
those showing only a delay in time to patent parasitaemia
(Po0.05) compared with other non-protected vaccinees (one-
way ANOVA with Bonferroni’s multiple comparison test,
Supplementary Fig. S3). Thus, the level of IFNg-secreting
monofunctional CD8þ T cells induced by vaccination
effectively stratiﬁed the degree of impact on the parasitaemia
observed, from complete liver clearance (sterile efﬁcacy) to
substantial but incomplete clearance (reﬂected in a delay to
patency), and to no detectable effect.
Discussion
Heterologous prime-boost immunization regimes have provided
a means of inducing strong T-cell immunity in pre-clinical
models. A priming immunization with a chimpanzee adenoviral
vector followed by an MVA boost here induced durable responses
of exceptional magnitude with a high proportion of cytokine-
secreting CD8þ T cells. The overall level of T-cell response
induced here is 5–10 fold higher than with previous prime-boost
regimes using the same antigenic insert17,18, with an equal
proportion of cytokine secreted from CD4þ and CD8þ T cells,
and much higher antigen-speciﬁc CD8þ T-cell responses than
those induced by DNA vaccines or irradiated sporozoites31,32.
Even without the MVA boost, the adenovirus-primed responses
here appear stronger than those reported with human adenoviral
vectors33 and this may in part reﬂect the very low level of anti-
vector immunity to simian vectors in humans34,35.
Two levels of pre-erythrocytic malaria vaccine performance
may be evaluated in phase IIa CHMI trials: sterile efﬁcacy where
all parasites are cleared at the pre-erythrocytic stages or delayed
patency17,18,36,37, or partial efﬁcacy, which is observed when
sufﬁcient parasites are cleared to produce a 2-day delay in time to
patency, corresponding to clearance of an estimated 495% of
pre-erythrocytic parasites29. Vaccinees showing delay in time to
patency have a substantially reduced parasite density in their
blood shortly after liver to blood infection, as shown by sensitive
PCR analyses (Supplementary Fig. S3 and Supplementary Table
S1). Three vaccinees here showed sterile efﬁcacy and ﬁve showed
delay totalling 8/14 (58%) with ChAd63-MVA, compared with
9/38 individuals (24%, P¼ 0.02, w2 test) with earlier DNA–MVA
and FP9–MVA regimes that used the same ME-TRAP malaria
insert17,18,28. In contrast, no sterile efﬁcacy or delay in time to
patency was observed in those administered the ChAd63 vector
without an MVA boost, underscoring the importance of
Table 1 | Analysis of potential immune correlates with time to parasitaemia.
Assay Population/response N Time point r P-value
TRAP ELISA IgG antibody titre 18 Challenge A 0.16 0.536
Functional Assay Neutralizing antibodies to ChAd63 24 Screening/Day 0
Challenges Aþ B
0.13 0.534
Ex vivo ELISPOT SFC’s/106 PBMC (TRAP peptides) 24 Challenges Aþ B 0.27 0.203
Cultured ELISPOT SFC’s/106 PBMC (TRAP peptides) 18 Challenge A 0.39 0.109
Flow cytometry CD4þ IFNgþ 18 Challenge A 0.46 0.056
CD4þ IFNgþ 14 (Ad-MVA) Challenges Aþ B 0.3 0.3
CD4þ IL-2þ 18 Challenge A 0.53 0.025*
CD4þ IL-2þ 14 (Ad-MVA) Challenges Aþ B 0.23 0.44
CD8þ IFNgþ 18 Challenge A 0.57 0.013*
CD8þ IFNgþ 14 (Ad-MVA) Challenges Aþ B 0.45 0.11
CD8þ IL-2þ 18 Challenge A 0.55 0.019*
CD8þ IL-2þ 14 (Ad-MVA) Challenges Aþ B 0.16 0.58
CD8þ TNFaþ 18 Challenge A 0.51 0.030*
CD8þ TNFaþ 14 (Ad-MVA) Challenges Aþ B 0.07 0.82
CD8þ IFNgþ (iMFI) 18 Challenge A 0.55 0.017*
CD8þ IFNgþ (iMFI) 14 (Ad-MVA) Challenges Aþ B 0.27 0.35
CD4þ IFNgþ/IL-2þ/TNFaþ 18 Challenge A 0.45 0.059
CD4þ IFNgþ/IL-2þ/TNFaþ 14 (Ad-MVA) Challenges Aþ B 0.26 0.37
CD8þ IFNgþ/IL-2þ/TNFaþ 18 Challenge A 0.47 0.052
CD8þ IFNgþ/IL-2þ/TNFaþ 14 (Ad-MVA) Challenges Aþ B 0.1 0.73
CD8þ IFNgþ/IL-2/TNFa 18 Challenge A 0.63 0.005*
CD8þ IFNgþ/IL-2/TNFa 8 (Ad-MVA) Challenge A 0.84 0.011*
CD8þ IFNgþ/IL-2/TNFa MFI 18 Challenge A 0.44 0.067
CD8þ IFNgþ/IL-2/TNFa iMFI 18 Challenge A 0.55 0.017*
CD8þ IFNgþ/IL-2/TNFa iMFI 14 (Ad-MVA) Challenges Aþ B 0.46 0.1
CD8þ CD107aþ/IFNg/IL-2/TNFa 14 Challenges Aþ 150 0.61 0.020*
CD8þ IFNgþ/IL-2/TNFa 6 (Ad-MVA) Challenge B 0.64 0.018*
CD8þ IFNgþ/IL-2/TNFa 24 Challenges Aþ B 0.61 0.0016*
CD8þ IFNgþ/IL-2/TNFa 14 (Ad-MVA) Challenges Aþ B 0.81 0.0005w
Correlation coefﬁcients between time to parasitaemia and different immune measures (two-tailed Spearman’s correlation). A total of 18 individuals (10 administered Ad alone and 8 Ad-MVA) were
included from challenge A and 6 (all administered Ad-MVA) from challenge B.
Regression models were ﬁtted to the log-transformed data using either frequency of CD4þ IFNgþ , CD8þ IFNgþ or both Tcell populations as the independent variable and time to parasitaemia as the
dependent variable and Akaike’s information criterion (AIC) was calculated for each. The best ﬁtting model was CD8þ IFNgþ (AIC 126.6) and the model with CD4þ IFNgþ alone as the independent
variable ﬁtted least well (AIC 130.4). Adding CD4þ IFNgþ to the CD8þ IFNgþ model did not improve the ﬁt signiﬁcantly (likelihood ratio test, P¼0.77). MFI and iMFI relate to IFNg staining.
*Statistically signiﬁcant at Po0.05.
wCorrection of this P-value by a factor of 10 to make a conservative Bonferroni correction for multiple comparisons yields a P-value of Pcorrected¼0.005.
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heterologous prime-boost immunization regimes for potent
CD8þ T-cell induction.
We show that CD8þ T cell levels comparable to those
achieved in macaque pre-clinical models24,38 can now be induced
in humans with a signiﬁcant correlation of CD8þ T-cell
immunogenicity with efﬁcacy. We show elsewhere that
comparable very potent immunogenicity can be induced with
these vaccine vectors using two other malaria inserts39,40, and
similar results with antigens from HCV41 suggest that this new
prime-boost approach may be widely applicable. Although several
T-cell subpopulations were weakly correlated with protection in
the ﬁrst arm, when the study was repeated, thereby increasing the
overall sample size, the weaker correlations became non-
signiﬁcant, with only the frequency of monofunctional IFNg-
secreting CD8þ T cells showing a signiﬁcant association with
protection when data from the two arms of the study were
combined. In this and previous studies23,36,37 the greater
magnitude of T-cell immunogenicity induced by ChAd-MVA
heterologous prime-boost immunization correlates with an
increase in the number of detectable epitopes recognized so it is
likely that increased breadth also correlates with efﬁcacy, and
distinguishing between these two will require larger studies.
Importantly, the levels of CD8þ T-cell response required for
efﬁcacy identiﬁed here, though substantial, are much lower than
the extremely high CD8þ T-cell levels required for efﬁcacy
in murine malaria models, possibly in part related to the longer
duration of the liver stage, typically 7 days versus 2 days10,11,
with P. falciparum than rodent Plasmodia spp. Interestingly,
the protective value of monofunctional IFNg-secreting T cells,
shown here in humans, is consistent with our recent murine
malaria data11.
To our knowledge a CD8þ T cell correlate of vaccine-induced
protection has not previously been reported in humans, although
there is evidence that CD4þ T-cell responses are relevant for
efﬁcacy of tuberculosis and possibly other vaccines42. These
results also suggest that single-vector immunization strategies
assessed previously in other diseases may simply have been too
weakly immunogenic to reach the threshold level needed for
signiﬁcant efﬁcacy.
The leading candidate malaria vaccine, RTS,S/AS01, does not
induce malaria-speciﬁc CD8þ T cells and appears to work
primarily through antibody induction against sporozoites, pre-
venting them entering liver cells43. We report here the second
highest level of statistically signiﬁcant efﬁcacy amongst 430
malaria vaccine candidates assessed in phase II trials, exceeded
only by RTS,S, which is currently in a large phase III trial in
Africa. Data from that trial recently showed an efﬁcacy of just
31% against clinical malaria when used in the key target
population of 6–12-week-old infants, possibly related to lower
than expected antibody immunogenicity in this age group20,21,
despite RTS,S having previously demonstrated 50% sterile efﬁcacy
in adults against CHMI37. It appears unlikely that RTS,S used
alone will offer a cost-effective vaccine of high efﬁcacy for
deployment, at least in the key target age group of young
infants20. However, importantly, combining partially effective
antibody and CD8þ T-cell-inducing vaccines leads to synergistic
efﬁcacy in murine malaria22.
The very high efﬁcacy levels observed pre-clinically with such a
combination approach are probably achieved by allowing T cells
to clear the liver of parasitized hepatocytes more effectively
after a partially effective anti-sporozoite vaccine has reduced
sporozoite and thereby infected hepatocyte numbers. Estimates
of the tiny numbers of sporozoites that survive the anti-
bodies induced by RTS,S to enter liver cells in human vaccinees29
further emphasize that CD8þ T-cell-inducing vaccines should be
more effective in combination with anti-sporozoite vaccines.
Hence, our observation of high level but often incomplete
clearance of pre-erythrocytic parasites in 8/14 vaccinees with a
liver-stage vaccine suggests that this vectored vaccine approach
could be particularly effective if combined with an additional
component, such as RTS,S, that targets sporozoites with
protective antibodies. So, we report here what could be a key
component for a highly efﬁcacious vaccine against malaria.
Assessment of the efﬁcacy and deployability of such combi-
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nation vaccine approaches is now a priority for malaria control
strategies, particularly as both approaches are currently in trials in
African infants21,44.
More generally, the feasibility of inducing protective CD8þ
T-cell immunity in humans using safe, readily manufactured,
non-replicating viral vectors offers the prospect of assessing
potent CD8þ T-cell-based vaccines in humans for prophylaxis
and immunotherapy of many infectious and non-infectious
diseases.
Methods
Clinical trial design. We conducted the study at Centre for Clinical Vaccinology
and Tropical Medicine and Vaccinology, University of Oxford, with the CHMI
procedure performed at Imperial College, London. We recruited healthy malaria
naı¨ve adults aged 18–50 years old from the Oxford area during Feb 2009 to Jan
2010 (inclusion and exclusion criteria are described in Supplementary Methods).
All volunteers gave written informed consent prior to participation and the study
was conducted according to the principles of the Declaration of Helsinki and in
accordance with Good Clinical Practice (GCP). Approvals were granted by the
Oxfordshire Research Ethics Committee (OXREC A 09/HO604/9) and the Medi-
cines and Healthcare products Regulatory Agency (EudraCT 2008-006804-46). The
trial was registered with ClinicalTrials.gov number NCT00890760. The Clinical
Biomanufacturing Facility, University of Oxford (ChAd63) and IDT Biologika,
Rosslau, Germany (MVA), manufactured study vaccines under Good Manu-
facturing Practice conditions. A Local Safety Monitor provided safety oversight and
GCP compliance was externally monitored.
We vaccinated 15 volunteers with ChAd63 ME-TRAP 5 1010 v.p. intramus-
cularly followed by MVA ME-TRAP 2 108 p.f.u. intradermally 56 days later. We
vaccinated another group of 10 volunteers with a single dose of ChAd63 ME-TRAP
5 1010 v.p. intramuscularly. Group allocation was non-randomized. Volunteers
attended clinical follow-up at days 2, 14 and 28 following ChAd63 ME-TRAP, and
at days 56, 63 and 76 following MVA ME-TRAP. Safety assessment including
blood sampling for safety was conducted as previously described17,18,23 (adverse
event assessment criteria are shown in Supplementary Tables S4–S7). One
volunteer in the prime-boost group in CHMI A was unable to proceed to challenge
having moved from the study area.
Five Anopheles stephensi mosquitoes, each with 102–104 sporozoites per salivary
gland, were allowed to bite each subject, thus delivering 3D7 strain P. falciparum
sporozoites, 14–21 days after the ﬁnal vaccination. This procedure took place over
2 days with the same number of vaccinees and controls exposed each day.
Monitoring took place twice daily by using Giemsa-stained thick blood ﬁlms,
which were considered positive if a single morphologically correct parasite was
seen, and by quantitative PCR starting on day 6.5 until day 14 and then once daily
until the end of the study period at day 21. Subjects were treated with Riamet after
the ﬁrst conﬁrmed positive blood ﬁlm or at day 21 if no parasitemia was detected.
In addition to vaccinated subjects, six unvaccinated subjects were infected with
malaria as infectivity controls. We reviewed volunteers at 35, 90 and 150 days
following challenge for safety and immunology assessment.
Sporozoite CHMI group sizes are typically small but power to detect differences
between the vaccinees and the controls is improved by the use of Kaplan–Meier
analysis of time to patent parasitaemia. Partially effective vaccines should delay
average time to parasitaemia in non-sterilely protected individuals if they protect
any number of volunteers fully. The primary endpoint analysis was time to patent
parasitaemia for the vaccine groups (prime-boost (n¼ 14) and ChAd63-alone
(n¼ 10)) compared with unvaccinated controls (n¼ 12) by Kaplan–Meier analysis
(two-tailed). Signiﬁcance testing used the log-rank test.
Immunological and molecular assays. Ex vivo (18-h stimulation) and cultured
ELISPOT (10-day stimulation) assays were performed using Multiscreen IP ELI-
SPOT plates (Millipore), human IFNg SA-ALP antibody kits (Mabtech) and BCIP
NBT-plus chromogenic substrate (Moss Inc). Cells were cultured in RPMI (Sigma)
containing 10% heat-inactivated, sterile-ﬁltered fetal calf serum, previously
screened for low reactivity (Labtech International). Antigens were tested in
duplicate with 250,000 PBMC added to each well of the ex vivo ELISPOT plate18
and 100,000 cultured T cells in the cultured ELISPOT assay. TRAP peptides were
20 amino acids in length, overlapping by 10 amino acids (Neopeptide), assayed in 6
pools of 7–10 peptides at 10mgml 1. Responses were averaged across duplicates,
responses in unstimulated (negative control) wells were subtracted and then
responses in individual pools were summed for each strain of the TRAP antigen.
ME responses were assayed in a single pool and peptide pool conﬁgurations are
shown in Supplementary Tables S2 and S3. Staphylococcal enzyme B
(0.04 mgml 1) and phytohaemmagglutinin-L (20 mgml 1) were used as a positive
control. Epitope mapping was performed using individual 20mer peptides
spanning the length of the T9/96 TRAP protein in single ELISPOT wells, each
containing 100,000 PBMC. Plates were counted using an AID automated ELISPOT
counter (AID Diagnostika GmbH, algorithm C), using identical settings for all
plates and counts were adjusted only to remove artefacts. Responses to the negative
control were always o80 SFC per million PBMC. Responses of 450 SFC per
million after subtraction of background were considered positive.
For ﬂow cytometry, responses were assessed by either a 7-colour (part A) or
12-colour (part B) staining panel, which was performed on freshly isolated PBMC,
in parallel with ELISPOT assays, aliquots of 1 106 cells in 1ml of medium
containing anti-CD28 and anti-CD49d at 1 mgml 1 (Becton Dickinson) and
62.5 mgml 1 of CD107a-PeCy5 (eBioscience)) in part B were stimulated with
either no antigen, a pool of all 56 peptides spanning the T9/96 strain of the TRAP
antigen (1mgml 1) or a positive control, Staphylococcal enterotoxin B (Sigma,
1 mgml 1) in 5ml polystyrene FACS tubes for 18 h. Brefeldin A and monensin,
both at 1 mgml 1, were added for the last 16 h. Cells were incubated with a dead
cell discrimination dye (VIVID, 1/80, Invitrogen), and then surface-stained
at 4C with CD4-APC (1/20, eBioscience) or CD4-Qdot 625 (1/50, Invitrogen),
CD14- and CD19-Paciﬁc Blue (both 1/50, Becton Dickinson). After permeabili-
sation, intracellular staining was performed at room temperature with CD3-PeCy5
(part A, 1/20, eBioscience) or CD3-Alexa Fluor 700 (part B, 1/100, eBioscience)
plus CD8-APC-Alexa Fluor 780 (1/50) and IFN-g-FITC (1/50), IL-2-PE (1/100)
and TNFa-Pe-Cy7 (1/50, all eBioscience) and ﬁxed in 4% paraformaldehyde.
Acquisition was performed on the day of staining on a BD LSRII; at least 500,000
events were collected per sample. Data was prepared and analysis performed using
FlowJo v8.8.6 (Treestar Inc,), Pestle v1.6 and Spice v5.05 (Mario Roederer, Vaccine
Research Centre, NIAID, NIH). Dead cells (Vividþ ), monocytes (CD14þ ) and B
cells (CD19þ ) were excluded from the analysis. A time gate was ﬁrst evaluated,
and then cells were gated on lymphocytes, singlets, live CD3þ , CD8þ or CD4þ
(excluding double-positives), and then IFNg and combinations of markers. A
sample gating strategy is provided in Supplementary Fig. S2. Responses to peptide
were determined after subtraction of the response in the unstimulated control for
each sample. Pie charts were created using absolute measures with a threshold of
0.001%. Mean ﬂuorescence integrity (MFI) was calculated using the geometric
mean of the cytokine-positive population and integrated MFI (iMFI) represents the
integration of the frequency with the geometric mean of the cytokine-secreting
population, giving a measure of total amount of cytokine production.
nAb titres to ChAd63 vector were determined as follows. One day prior to
assay, GripTite 293 cells (Invitrogen) were seeded in 96-well plates (3 104 cells/
well). Heat-inactivated test sera were diluted fourfold from 1:9 to 1:2,304 in 10%
fetal bovine sera (FBS) in DMEM and incubated 1:1 with ChAd63 expressing the
secreted alkaline phosphatase (SEAP) gene (8 107 vpml 1) for 1 h at 37 C.
Serum and virus were then added to 293 cells in a volume of 200 ml in duplicate for
1 h, after which serum and virus were aspirated and replaced with fresh 10% FBS in
DMEM. A virus-only control was included. After 22–26 h at 37 C, 50ml of
medium was assayed for SEAP activity using a Phospha-Light TROPIX
phosphatase assay (Applied Biosystems) in black assay plates and luminescence
was measured after 45min on a Thermo-Fisher Varioskan Flash Luminometer.
Anti-vector neutralization titres were deﬁned as the dilution of serum showing 50%
reduction in SEAP activity, based on observed % inhibition values relative to SEAP
activity from virus alone.
Anti-TRAP IgG ELISAs were performed in Nunc-Immuno Maxisorp 96-well
plates (Thermo Scientiﬁc) coated with 1 mgml 1 of TRAP protein in carbonate–
bicarbonate coating buffer (Sigma) overnight at 4 C. Plates were washed with PBS
Tween and blocked with 1% BSA in PBS. Sera were diluted at a starting
concentration of 1:100, added in duplicate and serially diluted threefold. Plates
were incubated for 2 h at room temperature and then washed as before. Goat anti-
human whole IgG conjugated to alkaline phosphatase (Sigma) was added for 1 h at
room temperature. Following a ﬁnal wash, plates were developed by adding
p-nitrophenylphosphate at 1mgml 1 in diethanolamine buffer (Pierce). Optical
density (OD) was read at 405 nm on an ELx800 microplate reader. Serum antibody
endpoint titres were taken as the x axis intercept of the dilution curve at an
absorbance value three s.d greater than the OD405 for serum before vaccination.
A standard positive serum sample was included in each assay as a reference control.
PCR for blood parasite density after CHMI used blood samples ﬁltered on custom
24-well Whatman VFE plates and washed with PBS to reduce white blood cell
numbers. DNA extraction was performed on 0.5ml of the ﬁltered blood using Qiagen
QIAamp Blood mini kit using a modiﬁed vacuum manifold protocol as follows:
volumes of protease, lysis buffer and ethanol were 40ml, 400ml and 400ml,
respectively, and wash buffer volumes increased to 750ml. The second wash buffer
allowed to soak on the DNA puriﬁcation columns for 2min before the vacuum was
applied. Columns were transferred to collection tubes and centrifuged at 13,000 r.p.m.
for 4min to dry. DNA was eluted with 50ml sterile 10mM Tris (pH 8.0), incubating
for 1min at room temperature before centrifugation (1min, 8,000 r.p.m.) to collect
the DNA sample. Quantitative PCR was performed on extracted DNA, amplifying a
133-bp product from the 18S ribosomal gene of P. falciparum in a TaqMan probe-
based QPCR using the following primers: forward- 50-GTAATTGGAATGATAGG
AATTTACAAGGT-30 , reverse 50-TCAACTACGAACGTTTTAACTGCAAC-30 and
a TaqMan probe 50-FAM-AACAATTGGAGGGCAAG-NFQ-MGB-30 (Applied
Biosystems)45,46. Triplicate reactions of 25ml were set up with 5ml DNA template,
12.5ml Universal PCR Master Mix, no Amperase UNG (Applied Biosystems), 1ml
forward primer, 1ml reverse primer, 0.25ml TaqMan Probe (all at 10 pmolml 1) and
5.25ml nuclease-free water. Reactions were run on an Applied Biosystems Step One
Plus PCR System with an initial 10min hot start activation at 95 C, followed by 15 s
denaturation at 95 C and a 60 s annealing and extension at 60 C for 45 cycles. Each
plate contained a no template control and a standard curve made by serial dilutions
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of a plasmid containing the 133-bp PCR product that had been adjusted to give a
parasites per ml equivalent (based on copies of 18S per parasite genome, blood
sample volume extracted from and volume of DNA template used per reaction) of
105, 104, 103, 3 102, 102, 4 101 and 2 101. Automatic quantitation was
performed with Applied Biosystems Step One plus software v2.1. Mean parasite
equivalent values of o20 or with only 1 positive replicate were classed as negative.
Laboratory staff performing blood ﬁlm microscopy and qPCR were blinded to the
group allocation of volunteers.
Data analysis and statistics. Time to parasitaemia as measured by thick-ﬁlm
microscopy was the primary efﬁcacy endpoint and this was analysed using
Kaplan–Meier log-rank test. Assessments of efﬁcacy compared unvaccinated
controls with groups of immunized volunteers. Immunological analysis compared
markers of T-cell immunogenicity (summed ex vivo and cultured ELISPOT
responses, and percentage of antigen-speciﬁc CD4þ and CD8þ cells by intra-
cellular cytokine staining) and antibody responses between groups. Group averages
(mean or median) were described. Signiﬁcance testing of differences between group
means (for normally distributed data as assessed by the D’Agostino and Pearson
omnibus normality test) used the two-tailed Student’s t-test, or medians used the
two-tailed Mann–Whitney U-test. Immunological correlations with time to patent
parasitaemia or other variables were pre-speciﬁed in the trial protocol as secondary
endpoints and prioritized analysis of T-cell subsets (particularly CD8þ sub-
populations), based on observations from pre-clinical studies with these vaccines.
Analyses were performed using the two-tailed Spearman’s rank correlation
co-efﬁcient (rs) as data were either non-normally distributed or the number of
observations was too small to allow an accurate estimation of the underlying
distribution. Correction of P-values for multiple comparisons was made using the
Bonferroni method, which multiplies the P value by the number of comparisons
assessed. For log-transformed PCR data, an arbitrary value of 1 was added to each
PCR value to allow log transformation of 0.0 values (y¼ log (1þ PCR)). The area
under curves was calculated using the trapezoid rule and compared between groups
as described above. Regression models were ﬁtted to log-transformed ﬂow cyto-
metry data with frequency of given T-cell populations as the independent variable
and time to parasitaemia as the dependent variable, and then Akaike’s information
criterion was used as an aid for choosing between competing models. Lower values
of the index indicate the preferred model, that is, the one with the fewest para-
meters that still provides an adequate ﬁt to the data. An alpha level of 0.05 was
considered statistically signiﬁcant. Statistical analysis was performed using Prism
5.0, Graph Pad Software.
Additional clinical information. Over 300 individuals had previously participated
in controlled human malaria infections by mosquito bite at the Oxford centre and
over a 1,000 further volunteers worldwide, all as part of vaccine studies. The clinical
trial methodologies have been found to be safe and have been reviewed
recently47,48. In this trial volunteers received as compensation sums ranging from
d1,500 to d1,800, varying according to the number of clinic visits made.
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